Influenza in Birds clinical trials
The registry lists 96 studies for Influenza in Birds across more than 10 countries. 2 are recruiting or about to start. 43 of them are mainly about Influenza in Birds (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-23.
Get an email when these change. Save the Influenza in Birds studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
National Institute of Allergy and Infectious Diseases (NIAID) (45) · Novartis Vaccines (8) · Seqirus (4) · Mahidol University (3) · St. Jude Children's Research Hospital (3) · Resilience Government Services, Inc. (3) · Inovio Pharmaceuticals (2) · Vical (2)
What is being tested here
Drugs under test in Influenza in Birds studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 5, phase 3 first
- Jan 2027A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults · Phase 3 · ModernaTX, Inc.
- Apr 2027Pandemic Influenza Vaccine in Organ Transplantation (PIVOT Trial) · Phase 3 · University Health Network, Toronto
- Feb 2027Immunogenicity and Safety of 2 Doses of Avian Influenza A (H5N1) Vaccine Administered 3 vs. 8 Weeks Apart · Canadian Immunization Research Network
- Jul 2027Smart Analysis and Decision-Making for Emerging Infectious Diseases · Peking University
- Aug 2027Safety and Immunogenicity of the Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented and Adjuvanted) in Adults and Older Adults · Butantan Institute
Who these studies take
Of the 1 Influenza in Birds studies recruiting now, 1 (100%) set no upper age limit and 0 (0%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (100%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 1 (100%) | 1 (100%) |
| 30 | 1 (100%) | 1 (100%) |
| 40 | 1 (100%) | 1 (100%) |
| 50 | 1 (100%) | 1 (100%) |
| 65 | 1 (100%) | 1 (100%) |
| 75 | 1 (100%) | 1 (100%) |
| 85 | 1 (100%) | 1 (100%) |
Across all 96 studies, recruiting or not: 73% stop at 75 or younger and 72% at 65; 13% take children; 0% are for women only and 3% for men only; 89% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Influenza in Birds studies take
Of 11 phase 2 interventional studies under Influenza in Birds, half reached primary completion within 17 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 2 | 17 mo4–19 · 11 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
Studies
Recruiting first, then most recently updated. Showing 50 of 96. Browse all 96 → or search them.
- Smart Analysis and Decision-Making for Emerging Infectious DiseasesEnrolling by invitationNCT07678619Not applicable1 country
- Safety and Immunogenicity of the Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented and Adjuvanted) in Adults and Older AdultsRecruitingNCT06842173Phase 1/21 country
- Pandemic Influenza Vaccine in Organ Transplantation (PIVOT Trial)Active, not recruitingNCT07240558Phase 31 country
- A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy AdultsActive, not recruitingNCT07496450Phase 32 countries
- A Study to Evaluate the Safety and Immunogenicity of Two Doses of a Novel H5 Central Antigen mRNA-LNP in Healthy AdultsCompletedNCT07019883Phase 11 country
- A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or UnprimedCompletedNCT05422326Phase 21 country
- A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older AdultsCompletedNCT06382311Phase 1/21 country
- Immunogenicity and Safety of 2 Doses of Avian Influenza A (H5N1) Vaccine Administered 3 vs. 8 Weeks ApartActive, not recruitingNCT07275060Phase 41 country
- Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.CompletedNCT00755703Phase 11 country
- A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of AgeCompletedNCT02839330Phase 31 country
- H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology AnalysesCompletedNCT02921997Phase 21 country
- H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: ImmunologyCompletedNCT03014310Phase 11 country
- Sanofi 2017 H7N9 With/Without AS03 in Adults/ElderlyCompletedNCT03312231Phase 21 country
- Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1CompletedNCT01006798Phase 11 country
- 2013/2017 H7N9 Prime-Boost IntervalCompletedNCT03589807Phase 21 country
- 2017 A/H7N9 IIV RevaccinationCompletedNCT03738241Phase 21 country
- Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian InfluenzaCompletedNCT03682120Phase 21 country
- Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4CompletedNCT03318315Phase 21 country
- Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59CompletedNCT03497845Phase 21 country
- Panblok H7 Vaccine Adjuvanted With AS03 or MF59CompletedNCT03283319Phase 21 country
- H5N1 With or Without Topical Aldara in Healthy AdultsCompletedNCT03472976Phase 11 country
- A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus VaccineCompletedNCT02251288Phase 11 country
- H7 Influenza Prime-Boost Regimens in Healthy Adults: Recombinant H7 DNA Plasmid Vaccine, VRC-FLUDNA071-00-VP, Administered Alone or With Monovalent Influenza Subunit Virion H7N9 Vaccine (MIV) as Prime With MIV Boost Compared to MIV Prime With MIV Boo...CompletedNCT02206464Phase 11 country
- H5N8 Mix and Match With or Without AS03 or MF59 in Healthy AdultsCompletedNCT02624219Phase 11 country
- H5N1 Vaccination With and Without AS03: Systems Biology AnalysisCompletedNCT01573312Phase 11 country
- Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 YearsCompletedNCT01928472Phase 11 country
- A Safety and Immunogenicity Study of IVACFLU-A/H5N1CompletedNCT02612909Phase 2/31 country
- Recombinant H7 Hemagglutinin Influenza Vaccine TrialCompletedNCT03038776Phase 11 country
- Safety Trial of Live Attenuated Influenza (H7N3) VaccineCompletedNCT01511419Phase 11 country
- Pandemic Influenza Plasmid DNA Vaccines (Needle-Free)CompletedNCT00694213Phase 11 country
- Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without Adjuvant System 03 (AS03)CompletedNCT01910519Phase 21 country
- Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly SubjectsCompletedNCT01766921Phase 24 countries
- Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in ChildrenCompletedNCT01776554Phase 22 countries
- Two Doses of GHB04L1 for Pandemic Influenza Prophylaxis in Healthy AdultsCompletedNCT03745274Phase 11 country
- H7N9 Boost in Healthy AdultsCompletedNCT02586792Phase 21 country
- Development of Immune Globulin Treatment for Avian FluTerminatedNCT00383071Phase 21 country
- A Follow-On Study With an H5 Influenza Vaccine for Subjects Who Participated in Study FLU-001CompletedNCT01403155Phase 11 country
- Study of VGX-3400X, H5N1 Avian Influenza Virus DNA Plasmid + Electroporation in Healthy AdultsCompletedNCT01142362Phase 11 country
- H7N9 Mix and Match With MF59 in Healthy Elderly PersonsCompletedNCT02213354Phase 21 country
- Vaccine for Prevention of Bird FluCompletedNCT00776711Phase 11 country
- Safety Study of Avian Flu VaccineCompletedNCT00408109Phase 11 country
- Safety and Dose Study of Peramivir for Influenza TreatmentCompletedNCT00297050Phase 11 country
- An Open-Label, Randomized Phase I Study in Healthy Adults of the Safety and Immunogenicity of Prime-Boost Intervals With Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc.) Administered Alone or Following Re...CompletedNCT01086657Phase 11 country
- Phase I Open-Label Study of Recombinant DNA Plasmid Vaccine, VRC-AVIDNA036-00-VP, Encoding for Influenza Virus H5 Hemagglutinin Protein Given IntradermallyCompletedNCT00489931Phase 11 country
- Safety and Immunogenicity of a Booster Dose of -H5N1 Influenza VaccineCompletedNCT00561184Phase 21 country
- Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults Unprimed and Primed With Adjuvanted or Non-adjuvanted Influenza VaccinesCompletedNCT00478816Phase 21 country
- Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Underlying Medical ConditionsCompletedNCT02091908Phase 31 country
- Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza VaccineCompletedNCT02107807Phase 33 countries
- A Retrospective, Observational Registry of Participants With Avian Influenza InfectionCompletedNCT02743676
- Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and AboveCompletedNCT00620815Phase 21 country